Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
NCT06561867

Ticagrelor Versus Cilostazol in Ischemic Stroke

Led by Kafrelsheikh University · Updated on 2024-08-20

900

Participants Needed

1

Research Sites

68 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Along with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever moderate and moderate to severe ischemic stroke compared to 200 mg cilostazol were assessed through NIHSS, mRS, and possible adverse effects.

CONDITIONS

Official Title

Ticagrelor Versus Cilostazol in Ischemic Stroke

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 75 years
  • First-ever moderate or moderate-to-severe ischemic stroke
  • Received antiplatelet treatment within 24 hours of stroke onset
  • Patients with previous transient ischemic attacks (TIA) allowed
  • Not eligible for rt-PA treatment
Not Eligible

You will not qualify if you...

  • No follow-up for 90 days after enrollment
  • NIH Stroke Scale score ≤ 4 or ≥ 25 or rapidly resolving symptoms before imaging
  • History of persistent or recurrent CNS diseases such as epilepsy, meningioma, multiple sclerosis, or head trauma with residual deficits
  • Clinical seizures at stroke onset
  • Major organ failure or active malignancy
  • Acute myocardial infarction within previous six weeks
  • Use of warfarin, regular ticagrelor within a week before admission, or chemotherapy within the past year
  • Active peptic ulcers, recent gastrointestinal surgery, or bleeding history within last year
  • Major surgery within last three months
  • Allergy to study drugs
  • Abnormal lab values: INR > 1.4, PT > 18, blood glucose < 50 or > 400 mg/dL, blood pressure < 90/60 or > 185/110 mmHg on admission, platelets < 100,000
  • Pregnant or lactating patients
  • Stroke due to venous thrombosis, cardiac arrest, or severe hypotension
  • Contraindications to the study drugs

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Kafr Elsheikh University Hospital

Kafr ash Shaykh, Egypt, 33511

Actively Recruiting

Loading map...

Research Team

M

mohamed G. Zeinhom, MD

CONTACT

S

sherihan R. ahmed, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here